Want to join the conversation?
$VRTX said that outside the U.S., reimbursement process for its cystic fibrosis treating drug Orkambi is ongoing. These discussions are progressing as anticipated by the company across Europe, Canada, and Australia. $VRTX believes that it will achieve reimbursements from European and other government payers as in the U.S.
$NFLX a monster move, going up. Expect making some money on Monday.
$AMD down more than 6% even after posting above consensus third quarter results.
$MCD stock rose more than 2% after it posted better than expected 3Q16 results, driven by global same-store sales growth. Meanwhile, earnings and revenue were lower than last year, hurt by refranchising efforts.